Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Enavogliflozin (DWP-16001) is an orally available small molecule and sodium glucose transporter 2 inhibitor.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 158.00 | |
5 mg | In stock | $ 397.00 | |
10 mg | In stock | $ 622.00 | |
25 mg | In stock | $ 1,080.00 | |
50 mg | In stock | $ 1,480.00 | |
100 mg | In stock | $ 1,960.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 437.00 |
Description | Enavogliflozin (DWP-16001) is an orally available small molecule and sodium glucose transporter 2 inhibitor. |
In vitro | Enavogliflozin (DWP-16001), a best-in-class antidiabetic agent, functions as a selective and orally active sodium-glucose cotransporter-2 (SGLT-2) inhibitor, as supported by references [1][2][3]. |
Synonyms | DWP-16001 |
Molecular Weight | 446.92 |
Formula | C24H27ClO6 |
CAS No. | 1415472-28-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (223.75 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Enavogliflozin 1415472-28-4 GPCR/G Protein SGLT agent DWP16001 sodium-glucose DWP-16001 inhibit selective orally Inhibitor cotransporter Sodium-dependent glucose cotransporters antidiabetic DWP 16001 inhibitor